Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11493975 | 0.88 | CYP2C9 (0.44) | CYP2C19CYP3A4CYP2C9 | |
| SCHEMBL3190736 | 0.86 | CYP2C19 (0.48) | CYP2C19SLC6A4SLC6A3SMN1; SMN2HIF1A | |
| SCHEMBL11690791 | 0.84 | PPARA (0.44) | ALDH1A1LMNACYP2C9 | |
| SCHEMBL10617967 | 0.82 | CYP2C19 (0.46) | CYP2C19SLC6A4SLC6A3SMN1; SMN2HIF1A | |
| SCHEMBL3190448 | 0.82 | SIGMAR1 (0.47) | CYP2C19SLC6A4SLC6A3SMN1; SMN2HIF1A | |
| SCHEMBL297345 | 0.82 | CYP2C19 (0.46) | CYP2C19SLC6A4SLC6A3SMN1; SMN2HIF1A | |
| SCHEMBL28138629 | 0.82 | CYP2C19 (0.46) | CYP2C19SMN1; SMN2HIF1ASIGMAR1ALDH1A1 | |
| SCHEMBL3200007 | 0.82 | CYP2C19 (0.50) | CYP2C19SLC6A4SLC6A3SMN1; SMN2HIF1A | |
| SCHEMBL957143 | 0.80 | CYP2C19 (0.44) | CYP2C19SLC6A4SLC6A3SMN1; SMN2HIF1A | |
| SCHEMBL658690 | 0.79 | KMT2A (0.54) | SMN1; SMN2HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455483-B2 | Compounds—801 | ASTRAZENECA AB (SE) | 2013-06-04 | — | — | US | disclosed |
| US-20110053909-A1 | Compounds - 801 | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| EP-0779261-A1 | Continuous process for racemization of benzylic alcohols, ethers, and esters by solid acid catalyst | UOP (US) | 1997-06-18 | — | — | EP | disclosed |
| US-5476964-A | Heating and flowing enamtiomorph through acidic ion exchange resin; recycling wastes | UOP (US) | 1995-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053909-A1 | Compounds - 801 | ADRA2C, ADRB2, ADRB1 | CYP2C19 331/4885SLC6A4 726/4885SLC6A3 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.